文献速递中医妇科中医内科中药与中成药合理使用

中药在卵巢子宫内膜异位囊肿术后长期管理中的作用:系统评价与Meta分析

Exploring the role of Chinese herbal medicine in the long-term management of postoperative ovarian endometriotic cysts: a systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2024-06-07

结果显示中药组复发率低于对照(OR=0.25)和西药组(OR=0.26),中药联合西药显著降低复发率(OR=0.26),并提高临床有效率、降低VAS评分和CA125水平、提高妊娠率。

要点

  • 中药可能降低术后卵巢子宫内膜异位囊肿复发率,联合西药效果更显著。
  • 中药可提高临床有效率、妊娠率,降低VAS评分和CA125水平。
  • 常用中药为桃仁、当归、丹参、赤芍、延胡索,多源自经典方剂。

核心结论

  • 中药可能是卵巢子宫内膜异位囊肿术后长期管理的可行选择,有潜力提高临床疗效、降低复发和不良反应。

主要发现

  • 中药组复发率低于对照(OR=0.25,95%CI 0.10-0.64)和西药组(OR=0.26,95%CI 0.11-0.65),中药联合西药降低复发率(OR=0.26,95%CI 0.17-0.40)。
  • 中药组临床有效率高于对照(OR=4.23,95%CI 1.12-15.99)和西药组(OR=2.94,95%CI 1.34-6.43),联合西药提高有效率(OR=3.44,95%CI 2.37-5.00)。
  • 中药降低VAS评分优于单用手术(MD=-0.86,95%CI -1.01至-0.71),联合西药改善疼痛(MD=-0.87,95%CI -1.10至-0.65)。
  • 中药降低CA125优于西药(MD=-11.08,95%CI -21.75至-0.42),联合西药降低CA125(MD=-5.31,95%CI -7.27至-3.36)。
  • 中药提高妊娠率优于手术(OR=3.95,95%CI 1.60-9.74)或西药(OR=3.31,95%CI 1.40-7.83),联合西药提高妊娠率(OR=2.99,95%CI 1.28-6.98)。

关键数值与推荐

  • 复发率:中药 vs 对照 OR=0.25(95%CI 0.10-0.64);中药 vs 西药 OR=0.26(95%CI 0.11-0.65);中药+西药 OR=0.26(95%CI 0.17-0.40)。
  • 临床有效率:中药 vs 对照 OR=4.23(95%CI 1.12-15.99);中药 vs 西药 OR=2.94(95%CI 1.34-6.43);中药+西药 OR=3.44(95%CI 2.37-5.00)。
  • VAS评分:中药 vs 手术 MD=-0.86(95%CI -1.01至-0.71);中药 vs 西药 MD=-0.16(95%CI -0.49至0.17);中药+西药 MD=-0.87(95%CI -1.10至-0.65)。
  • CA125:中药 vs 西药 MD=-11.08(95%CI -21.75至-0.42);中药+西药 MD=-5.31(95%CI -7.27至-3.36)。
  • 妊娠率:中药 vs 手术 OR=3.95(95%CI 1.60-9.74);中药 vs 西药 OR=3.31(95%CI 1.40-7.83);中药+西药 OR=2.99(95%CI 1.28-6.98)。

临床怎么用

  • 可考虑在卵巢子宫内膜异位囊肿术后长期管理中应用中药,尤其联合西药以降低复发、提高疗效和妊娠率。
  • 常用中药包括桃仁、当归、丹参、赤芍、延胡索,多源自经典方剂,可作为组方参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian endometriotic cysts (OEC) represent the primary manifestation of endometriosis, constituting a hormonally dependent inflammatory disorder in gynecology. It significantly affects the quality of life and reproductive health of women. It is worth noting that traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM), has been widely applied in mainland China due to its unique therapeutic system and commendable clinical efficacy, bringing new hope for preventing and managing OEC. OBJECTIVE: This study aims to evaluate the efficacy and safety of CHM in the management of postoperative OEC. Simultaneously, it seeks to explore the medication laws, therapeutic principles, and specific treatment mechanisms of CHM. METHODS: Eight electronic databases were searched from their inception to 01 November 2023. Randomized controlled trials (RCTs) assessing the therapeutic effects and safety of CHM for postoperative OEC were included. The risk of bias for each trial was assessed using the Cochrane Collaboration's tool. The certainty of the evidence was evaluated using the GRADE profiler 3.2. Additionally, we extracted formulation from the included studies, conducting a thorough analysis. RESULTS: (ⅰ) Twenty-two RCTs involving 1938 patients were included. In terms of the primary efficacy outcome, the CHM group demonstrated a potentially lower recurrence rate compared to both control (odds ratio (OR) = 0.25; 95% confidence intervals (CI): 0.10-0.64) and conventional western medicine (CWM) (OR = 0.26; 95% CI: 0.11-0.65) groups. Furthermore, the joint application of CHM and CWM resulted in a significant reduction in the recurrence rate (OR = 0.26; 95% CI: 0.17-0.40). (ⅱ) Regarding secondary efficacy outcomes, (a) Total clinical efficacy rate: CHM showcased an augmentation in clinical effectiveness compared to both the control (OR = 4.23; 95% CI: 1.12-15.99) and CWM (OR = 2.94; 95% CI: 1.34-6.43) groups. The combined administration of CHM and CWM substantially enhanced overall clinical effectiveness (OR = 3.44; 95% CI: 2.37-5.00). (b) VAS Score: CHM exhibited the capacity to diminish the VAS score in comparison to surgery alone (Mean difference (MD) = -0.86; 95% CI: -1.01 to -0.71). Nevertheless, no substantial advantage was observed compared to CWM alone (MD = -0.16; 95% CI: -0.49 to 0.17). The integration of CHM with CWM effectively ameliorated pain symptoms (MD = -0.87; 95% CI: -1.10 to -0.65). (c) Serum Level of Cancer antigen 125 (CA125): the CHM group potentially exhibited lower CA125 levels in comparison to CWM alone (MD = -11.08; 95% CI: -21.75 to -0.42). The combined intervention of CHM and CWM significantly decreased CA125 levels (MD = -5.31; 95% CI: -7.27 to -3.36). (d) Pregnancy Rate: CHM exhibited superiority in enhancing the pregnancy rate compared to surgery (OR = 3.95; 95% CI: 1.60-9.74) or CWM alone (OR = 3.31; 95% CI: 1.40-7.83). The combined utilization of CHM and CWM demonstrated the potential to enhance pregnancy rates compared to CWM (OR = 2.99; 95% CI: 1.28-6.98). Concerning safety outcome indicators, CHM effectively decreased the overall incidence of adverse events and, to a certain extent, alleviated perimenopausal symptoms as well as liver function impairment. (ⅲ) Most of CHMs were originated from classical Chinese herbal formulas. Prunus persica (L.) Batsch (Taoren), Angelica sinensis (Oliv.) Diels (Danggui), Salvia miltiorrhiza Bunge (Danshen), Paeonia lactiflora Pall. (Chishao), and Corydalis yanhusuo W.T.Wang (Yanhusuo) were most frequently used CHM. CONCLUSION: CHM may be a viable choice in the long-term management of postoperative OEC, with the potential to enhance clinical efficacy while decreasing recurrence and adverse effects.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ding D, Liu S, Liu F, et al. Exploring the role of Chinese herbal medicine in the long-term management of postoperative ovarian endometriotic cysts: a systematic review and meta-analysis. Front Pharmacol. 2024. PMID: 38910886. doi:10.3389/fphar.2024.1376037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。